Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges

Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted Fast Track Designation by the United States ... Read More